Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains an important public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis, while in developed countries, factors for development include diabetes, obesity and non-alcoholic steatohepatitis (NASH). For unresectable HCC, the standard of care, Bayer’s Nexavar (sorafenib), prolongs survival by just three months, therefore more treatment options are needed.
This report provides an assessment of the pipeline, clinical, and commercial landscape of HCC. Overall, GlobalData expects new drug approvals to drive HCC market growth over the next decade (2016–2026).
GlobalData’s Hepatocellular Carcinoma: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
• Clinical Trial Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
• Commercial Assessment—leading marketed products, current and future players
• Competitive Landscape Analysis—key market events (2016–2026)
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global HCC market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Merck & Co.
F. Hoffmann-La Roche
Jiangsu Hengrui Medicine
Suzhou Zelgen Biopharmaceutical
Shenogen Pharma Group
Table of Contents
Table of Contents (PowerPoint Deck)
1.1 Table of Contents
1.3 Related Reports
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3.1 Report Scope
3.2 Disease Overview and Epidemiology
4 Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Target/MOA
4.4 Drug Review Designations
4.5 Products in Clinical Development
5 Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in Hepatocellular Carcinoma
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics
6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current and Future Players
7 Competitive Landscape Analysis (2016–2026)
7.1 Events Classification Overview
8.3 Key Events Included in the Analysis
8.4 About the Authors
8.5 About GlobalData
8.6 Contact Us
Tel +44 (0) 20 7947 2960
Personal and transaction information are kept safe from unauthorised use.